Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?-Reference-Cited by-同舟云学术

Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?

Published:2018-12 Issue: Volume:71 Page:47-58
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Remon J.,Hendriks L.E.,Cabrera C.,Reguart N.,Besse B.

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference137 articles.

1. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study;Gettinger;J Clin Oncol Off J Am Soc Clin Oncol,2018

2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

3. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet Lond Engl,2016

5. Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non-small cell lung cancer;Fehrenbacher;J Thorac Oncol Off Publ Int Assoc Study Lung Cancer,2018

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations;BMC Cancer;2024-08-03

2. Identification of a prognosis-related gene signature and ceRNA regulatory networks in lung adenocarcinoma;Heliyon;2024-04

3. Molecular pathology of non‐small cell carcinoma;Histopathology;2023-11-07

4. Single-cell analysis reveals exosome-associated biomarkers for prognostic prediction and immunotherapy in lung adenocarcinoma;Aging;2023-10-24

5. Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis;Frontiers in Oncology;2022-11-10